New @TheLancet Exenatide, a GLP-1 drug failed to improve #Parkinsons disease motor features (or slow progression) vs placebo in a small Phase 3 randomized, controlled trial https://
thelancet.com/journals/lance
t/article/PIIS0140-6736(24)02808-3/fulltext
…
GLP-1 Drug Exenatide Fails to Improve Parkinson’s Disease Progression
By
–
